CureVac Announces Dosing of First Participant in Phase 2 Study in Seasonal Influenza
Tuesday, 28 May 2024, 08:32
CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza
CureVac has initiated the Phase 2 study in seasonal influenza with the dosing of the first participant. The collaboration with GSK signifies a pivotal step forward in the development of potential solutions for seasonal flu. The joint effort reflects a commitment to leveraging combined expertise and resources to tackle healthcare challenges in the field of influenza.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.